2017, Number 4
Rev Hematol Mex 2017; 18 (4)
Non-Hodgkin lymphoma and infection due to human immunodeficiency virus. Ten-year experience in a university referral center
Sotomayor-Duque G, Colunga-Pedraza PR, Colunga-Pedraza JE, Lozano-Morales RE, Bugarín-Estrada E, Gómez-Almaguer D
PDF size: 96.68 Kb.
ABSTRACTBackground: Human immunodeficiency virus (HIV) infection is associated with an increased risk of malignancies. With the introduction of antiretroviral therapy, prognosis has improved significantly.
Objetive: To analyze the clinical behavior, evolution and prognosis of patients diagnosed with HIV and non-Hodgkin lymphoma at our center.
Material and Method: A retrospective analysis was done with all patients diagnosed with non-Hodgkin lymphoma and HIV from 2007 to 2017. We describe clinical characteristics and prognosis.
Results: A total of 31 patients were included. Median age was 41 years (25-64). All patients were male. The median follow-up was 6 months (1-54). The most common histological variety was plasmablastic lymphoma (n = 10). The most frequent first-line therapy was R-CHOP/CHOP (n = 17). The global response was 43.7% (n = 14). The median survival was 8 months (95% CI 2.89-13.1). The 2-year overall survival was 32%. The main cause of death was the progression of disease (50%, n = 8).
Conclusions: The diagnosis of HIV and non-Hodgkin lymphoma represents a real challenge; the proper management, timely diagnosis and early antiretroviral treatment of these patients are essential.